Kennedy R. Lees
A5108080058- Acute Ischemic Stroke Management
- Cerebrovascular and Carotid Artery Diseases
- Stroke Rehabilitation and Recovery
- Venous Thromboembolism Diagnosis and Management
- Intracerebral and Subarachnoid Hemorrhage Research
- Traumatic Brain Injury and Neurovascular Disturbances
- Atrial Fibrillation Management and Outcomes
- S100 Proteins and Annexins
- Blood Pressure and Hypertension Studies
- Antiplatelet Therapy and Cardiovascular Diseases
- Health Systems, Economic Evaluations, Quality of Life
- Neurological Disorders and Treatments
- Neurosurgical Procedures and Complications
- Gout, Hyperuricemia, Uric Acid
- Clinical practice guidelines implementation
- Peripheral Artery Disease Management
- Neurological Disease Mechanisms and Treatments
- Cardiovascular Health and Disease Prevention
- Lipoproteins and Cardiovascular Health
- Meta-analysis and systematic reviews
- Neuroscience and Neuropharmacology Research
- Heart Failure Treatment and Management
- Cardiac Imaging and Diagnostics
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiovascular Function and Risk Factors
University of Glasgow
2015-2025
Western Infirmary
2009-2023
Health and Education Research Management and Epidemiologic Services (United States)
2023
University of Nottingham
2007-2021
Karolinska Institutet
2008-2021
Karolinska University Hospital
2008-2021
Tampere University Hospital
2021
Tampere University
2021
Hospital de São José
2021
Cedars-Sinai Medical Center
2010-2020
Intravenous thrombolysis with alteplase is the only approved treatment for acute ischemic stroke, but its efficacy and safety when administered more than 3 hours after onset of symptoms have not been established. We tested between 4.5 a stroke.
This article represents the update of European Stroke Initiative Recommendations for Management. These guidelines cover both ischaemic stroke and transient attacks, which are now considered to be a single entity. The covers referral emergency management, Unit service, diagnostics, primary secondary prevention, general treatment, specific treatment including acute management complications, rehabilitation.
Background and Purpose— Most acute ischemic stroke patients arrive after the 3-hour time window for recombinant tissue plasminogen activator (rtPA) administration. The Desmoteplase In Acute Ischemic Stroke trial (DIAS) was a dose-finding randomized designed to evaluate safety efficacy of intravenous desmoteplase, highly fibrin-specific nonneurotoxic thrombolytic agent, administered within 3 9 hours onset in with perfusion/diffusion mismatch on MRI. Methods— DIAS placebo-controlled,...
Parasitoid Wasp Genomes wasps, which prey on and reproduce in host insect species, play important roles plant herbivore interactions, may provide valuable tools the biological control of pest species. The Nasonia Genome Working Group (p. 343 ; see news story by Pennisi ) presents genome three very closely related species: vitripennis, N. giraulti , longicornis . findings document rapid evolution between a endosymbiont that can cause nuclear-cytoplasmic incompatibilities affect speciation.
Evidence for efficacy of dual antiplatelet therapy in stroke is limited. Symptomatic carotid stenosis patients are at high risk early recurrent stroke. In this group, asymptomatic microembolic signals (MES), detected by transcranial Doppler ultrasound (TCD), markers future and transient ischemic attack (TIA) risk. They offer a surrogate marker to evaluate therapy, but no multicenter study has evaluated the feasibility approach.Clopidogrel Aspirin Reduction Emboli Carotid Stenosis (CARESS)...
The free-radical–trapping agent NXY-059 showed promise as a neuroprotectant in the Stroke–Acute Ischemic NXY Treatment I (SAINT I) trial, reducing disability when given to patients who had acute ischemic stroke. We sought confirmation of efficacy second, larger trial.
NXY-059 is a free-radical-trapping agent that neuroprotective in animal models of stroke. We tested whether it would reduce disability humans after acute ischemic stroke.We conducted randomized, double-blind, placebo-controlled trial involving 1722 patients with stroke who were randomly assigned to receive 72-hour infusion placebo or intravenous within 6 hours the onset The primary outcome was at 90 days, as measured according scores on modified Rankin scale for (range, 0 5, indicating no...
Desmoteplase is a novel plasminogen activator with favorable features in vitro compared available agents. This study evaluated safety and efficacy of intravenous (IV) desmoteplase patients perfusion/diffusion mismatch on MRI 3 to 9 hours after onset acute ischemic stroke.DEDAS was placebo-controlled, double-blind, randomized, dose-escalation investigating doses 90 microg/kg 125 desmoteplase. Eligibility criteria included baseline National Institute Health Stroke Scale (NIHSS) scores 4 20...
<h3>Abstract</h3> <b>Objective:</b> To determine whether raised plasma glucose concentration independently influences outcome after acute stroke or is a stress response reflecting increased severity. <b>Design:</b> Long term follow up study of patients admitted to an unit. <b>Setting:</b> Western Infirmary, Glasgow. <b>Subjects:</b> 811 with confirmed by computed tomography. Analysis was restricted the 750 non-diabetic patients. <b>Main measures:</b> Survival time and placement three months...
Abstract Ticks transmit more pathogens to humans and animals than any other arthropod. We describe the 2.1 Gbp nuclear genome of tick, Ixodes scapularis (Say), which vectors that cause Lyme disease, human granulocytic anaplasmosis, babesiosis diseases. The large reflects accumulation repetitive DNA, new lineages retro-transposons, gene architecture patterns resembling ancient metazoans rather pancrustaceans. Annotation scaffolds representing ∼57% genome, reveals 20,486 protein-coding genes...
Background and Purpose Clinical trials routinely use stroke scales to compare baseline characteristics of treatment groups. It is unclear which scale provides the most prognostic information. This often leads collection multiple in clinical trials. We aimed determine several commonly used best predicted outcome. Methods A single observer scored consecutive admissions an acute unit on National Institutes Health Stroke Scale (NIHSS), Canadian Neurological Scale, Middle Cerebral Artery Score....
Background and Purpose— The Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST) unadjusted results demonstrated that intravenous alteplase is well tolerated the effects were comparable with those seen randomized, controlled trials (RCTs) when used routine clinical practice within 3 hours ischemic stroke onset. We aimed to identify outcome predictors adjust outcomes SITS-MOST baseline characteristics RCTs. Methods— study population was (n=6483) pooled RCTs (n=464)...
UK-279,276 (neutrophil inhibitory factor) reduced infarct volume in a rat middle cerebral artery occlusion reperfusion model. ASTIN (Acute Stroke Therapy by Inhibition of Neutrophils) was an adaptive phase 2 dose-response-finding, proof-of-concept study to establish whether improves recovery acute ischemic stroke. The prime objective determine the dose that gave clinically relevant effect patients.A Bayesian sequential design with real-time efficacy data capture and continuous reassessment...
The original version of this consensus statement on mechanical thrombectomy was approved at the European Stroke Organisation (ESO)-Karolinska Update conference in Stockholm, 16-18 November 2014. has later, during 2015, been updated with new clinical trials data accordance a decision made conference. Revisions have face-to-face meeting ESO Winter School Berne February, through email exchanges and final then by each society. recommendations are identical to evidence level upgraded 20 February...